Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07037277 | C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV | PHASE3 | RECRUITING | 880 | — | — | Jun 2, 2025 | Mar 1, 2027 | Apr 13, 2026 | 106 | France, Germany +14 |
| NCT06868264 | C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV | PHASE3 | ACTIVE NOT_RECRUITING | 880 | — | — | Apr 7, 2025 | Dec 1, 2026 | Dec 5, 2025 | 105 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| Bemnifosbuvir - Ruzasvir (BEM/RZR) | EXPERIMENTAL | - |
| Sofosbuvir-Velpatasvir (SOF/VEL) | ACTIVE_COMPARATOR | - |
| Bemnifosbuvir-Ruzasvir (BEM/RZR) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Bemnifosbuvir-Ruzasvir | DRUG | BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis) |
| Sofosbuvir-Velpatasvir | DRUG | SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks |
| Bemnifosbuvir-Ruzasvir (BEM/RZR) | DRUG | BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis) |
| Sofosbuvir-Velpatasvir (SOF/VEL) | DRUG | SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks |
Key Inclusion Criteria: * Use of adequate contraception for females of childbearing potential * Must be direct-acting antiviral (DAA)-treatment-naïve (never exposed to an approved or experimental DAA for HCV) * Documented medical history compatible with chronic HCV * Either no liver cirrhosis or wi...